- Home
- EVN vs AUTL Comparison
EVN vs AUTL Comparison
Compare EVN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | AUTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.6M | 431.2M |
| IPO Year | 1998 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EVN | AUTL |
|---|---|---|
| Price | $10.20 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 96.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $85.73 |
| Revenue Next Year | N/A | $70.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.59 | $1.11 |
| 52 Week High | $11.23 | $2.70 |
Technical Indicators
Market Signals| Indicator | EVN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 44.93 |
| Support Level | $10.31 | $1.32 |
| Resistance Level | $11.15 | $1.52 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 31.07 | 58.46 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.